Persistence Market Research

U.S. Bacterial Conjunctivitis Drugs Market to Progress Rapidly, Boosted by Rising Incidence of Bacterial Ophthalmic Infections

Bacterial conjunctivitis is one of the common eye problems faced worldwide, usually caused by various bacterium such as Staphylococcus aureus, Streptococcus pneumonia, Moraxella lacunata, Haemophilus influenza, and others


New York, NY -- (SBWIRE) -- 01/19/2016 -- Persistence Market Research has published a new research report on the U.S. bacterial conjunctivitis drugs market. As per the report, the cost of treating bacterial conjunctivitis in the United States ranges from US$377 mn to US$857 mn annually. As per the Journal of the American Medical Association (JAMA), the incidence of bacterial conjunctivitis in the United States is 135 in 10,000 people.

Bacterial conjunctivitis is a common eye problem caused by numerous bacteria such as Streptococcus pneumonia, Haemophilus influenza, Staphylococcus aureus, Moraxella lacunata, and others. Bacterial conjunctivitis is self-limiting and acute and does not lead to major health issues. Antibiotics or medicines in the form of eye drops are generally prescribed by optometrists and ophthalmologists to treat bacterial conjunctivitis.

Request sample of this report:

The U.S. bacterial conjunctivitis drugs market is segmented into antibacterial drug classes such as macrolides, fluoroquinolones, and aminoglycosides. The fluoroquinolones segment is sub-segmented into ofloxacin, moxifloxacin, besifloxacin, ciprofloxacin, levofloxacin, and gatifloxacin.

The aminoglycosides segment is sub-segmented into gentamycin and tobramycin, whereas the macrolides segment is sub-segmented into erythromycin and azithromycin. In 2013, the fourth-generation fluoroquinolones segment emerged as the leading segment, accounting for 70% of the U.S. bacterial conjunctivitis drugs market. Considering their broad spectrum activity and high effectiveness against antibiotic-resistant bacterial strains, the fluoroquinolones segment is expected to maintain its dominant position till 2024. Factors such as the arrival of generic formulations in the market, imminent patient expirations of branded formulations including moxeza, vigamox, and besivance, and increasing prevalence of drug-resistant bacterial strains are expected to hamper the growth of the fluoroquinolones segment in the years to come.

In the U.S., the majority of the people suffering from bacterial conjunctivitis are treated by medical care physicians rather than eye care specialists. Around 1% of the primary care visits are related to bacterial conjunctivitis in the U.S. Bacterial infestation is considered to be the second most common reason of infectious conjunctivitis. Bacterial infestation accounts for around 50% to 75% cases, especially among children. Increasing incidence of bacterial conjunctivitis is the prime factor expected to drive the U.S. bacterial conjunctivitis drugs market in the years to come. However, rising genericization of antibacterial medicines is expected to weaken the growth of the U.S. bacterial conjunctivitis drugs market in the coming few years.

At present, the U.S. bacterial conjunctivitis drugs market is highly competitive and fragmented due to the involvement of small-scale pharmaceutical companies as well as several large-scale companies. Some of the leading companies operating in the U.S. bacterial conjunctivitis drugs market are Actavis plc, Bayer AG, Merck & Co., Inc., Perrigo Company plc, Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc., Akorn, Inc., F. Hoffmann-La Roche, Ltd., Novartis AG, and Pfizer, Inc.

View Detail Report:

Entry of new companies in the U.S. bacterial conjunctivitis drugs market is expected to increase the level of competition in the next few years. The leading players in the U.S. bacterial conjunctivitis drugs market are focusing on covering wider geographical areas to maintain their dominant position. The rising number of acquisitions of and mergers with new entrants is expected to create growth opportunities for the leading companies in the years to come.

About Persistence Market Research (PMR)
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.